Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:04 AM
Ignite Modification Date: 2025-12-25 @ 10:02 PM
NCT ID: NCT03820258
Description: The Safety Analysis Set included participants received at least 1 dose of study drug.
Frequency Threshold: 5
Time Frame: First dose date up to the last dose date (maximum: 8 Weeks) plus 30 days
Study: NCT03820258
Study Brief: Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
SOF/VEL/VOX FDC Direct-acting antiviral (DAA) - naive participants without cirrhosis (12 to \< 18 years old) received sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose (FDC) combination (400/100/100 mg tablet) orally once daily in nonfasting state for 8 weeks. A single placebo to match tablet was administered during screening until Day 1 to confirm the participant was able to swallow SOF/VEL/VOX 400/100/100 mg tablets. 0 None 1 21 13 21 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Hypotension SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (22.1) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (22.1) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (22.1) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (22.1) View
Asthenia SYSTEMATIC_ASSESSMENT General disorders MedDRA (22.1) View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA (22.1) View
Rhinitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (22.1) View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (22.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (22.1) View
Cough SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (22.1) View